M. Mcjannett

发表

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.

M. Stockler, I. Davis, M. Hofman, 2022, The Lancet. Oncology.

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

M. Stockler, W. Parulekar, M. Frydenberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience

H. Dhillon, C. Paterson, N. Roberts, 2022, Asia-Pacific journal of clinical oncology.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2019, The New England journal of medicine.

TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

M. Stockler, I. Davis, M. Hofman, 2019, BJU international.

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

M. Stockler, A. Scott, C. Gedye, 2021, The Lancet.

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, European urology.

ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)

M. Stockler, C. Gedye, I. Davis, 2021, BJU international.

e‐TC: Development and pilot testing of a web‐based intervention to reduce anxiety and depression in survivors of testicular cancer

M. Stockler, A. Wootten, B. Tran, 2017, European journal of cancer care.

Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.

A. Oza, P. Butow, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

M. Stockler, W. Parulekar, M. Frydenberg, 2023, The Lancet. Oncology.

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

M. Stockler, C. Gedye, I. Davis, 2020 .

Cancer in older people: a tale of two disciplines

D. Goldstein, C. Steer, G. Marx, 2009, Internal medicine journal.

Asking questions can help: development of a question prompt list for cancer patients seeing a surgeon

P. Butow, M. Tattersall, J. Thompson, 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.